CASTRATION-RESISTANT PROSTATE CARCINOMA
Clinical trials for CASTRATION-RESISTANT PROSTATE CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CARCINOMA trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Smart scans may boost radiation success in advanced prostate cancer
Disease control OngoingThis study tests whether a special scan called PSMA PET can help pick men with castration-resistant prostate cancer that has spread to the bones who will get the most benefit from Ra-223 radiation therapy. Ra-223 is a radioactive drug that targets bone tumors. The trial enrolled …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New drug combo shows promise against tough prostate cancer
Disease control OngoingThis study tests whether adding cediranib to olaparib works better than olaparib alone for men with a type of advanced prostate cancer that has spread and stopped responding to hormone therapy. About 90 men will take part. The goal is to see if the combination can slow cancer gro…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:10 UTC
-
New combo aims to slow bone metastases in tough prostate cancer
Disease control OngoingThis study looks at whether adding a radiation drug (radium-223) to standard hormone therapy (enzalutamide) can better control prostate cancer that has spread to bone. About 30 men with castration-resistant prostate cancer will be randomly assigned to get enzalutamide alone or wi…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 17, 2026 03:01 UTC
-
New drug combo targets hard-to-treat metastatic cancers
Disease control OngoingThis early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:00 UTC
-
New combo therapy aims to shrink advanced tumors
Disease control OngoingThis study tests the safety and effectiveness of combining the immunotherapy drug avelumab with other treatments (utomilumab, anti-OX40 antibody, and radiation) in people with advanced cancers that have spread. About 173 adults whose cancer has not responded to standard therapies…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:59 UTC
-
New hope for tough prostate cancer: drug cocktail trial underway
Disease control OngoingThis study tests different combinations of approved drugs to see which works best for men with advanced prostate cancer that has stopped responding to hormone therapy. About 200 men will receive either a standard hormone-blocking combo or that combo plus an immunotherapy or chemo…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 02:58 UTC
-
Double-Drug attack shows promise against tough prostate cancer
Disease control OngoingThis study tests whether adding rucaparib to standard enzalutamide helps men with advanced prostate cancer that has spread and stopped responding to hormone therapy. About 61 men will receive either the combination or enzalutamide alone. The goal is to see if the combo delays can…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 17, 2026 02:58 UTC
-
Immunotherapy plus chemo shows promise against Tough-to-Treat cancers
Disease control OngoingThis early-phase trial studies whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. About 15 participants with cancer that has spread will receive the co…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Targeted drug shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a drug called M1774 in 20 men with advanced prostate cancer that has a specific gene change (SPOP mutation) and is no longer responding to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The goal is to see if M1774 can…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New hope for tough prostate cancer: Two-Drug attack after chemo
Disease control OngoingThis study tests a two-step treatment for men with an aggressive form of prostate cancer that has spread. First, patients get chemotherapy plus an immunotherapy drug. Then, they take a maintenance pill (niraparib) either alone or with more immunotherapy. The goal is to see if thi…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:04 UTC
-
New drug combo shows promise for Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a combination of two drugs—olaparib and radium-223—in men with castration-resistant prostate cancer that has spread to bone. Olaparib blocks a protein that helps cancer cells repair themselves, while radium-223 delivers radiation directly to bone tumors. The goal…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Immunotherapy drug shows promise for Tough-to-Treat prostate cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab can help men with advanced prostate cancer that has stopped responding to the hormone therapy enzalutamide. About 58 men whose cancer continued to grow despite enzalutamide will receive pembrolizumab. The main g…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Double-Drug attack shows promise for tough prostate cancer
Disease control OngoingThis study tests whether adding the chemotherapy drug cabazitaxel to the hormone therapy abiraterone works better than abiraterone alone for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. About 223 men who have already r…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug combo aims to shrink tough prostate tumors
Disease control OngoingThis study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combo can lower PSA …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
New drug combo shows promise against Hard-to-Treat prostate cancer
Disease control OngoingThis study tests whether combining two drugs—golimumab (which reduces inflammation) and apalutamide (which blocks male hormones)—can shrink or slow advanced prostate cancer that no longer responds to standard hormone therapy. Eight men with metastatic castration-resistant prostat…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
New hope for Tough-to-Treat prostate cancer in clinical trial
Disease control OngoingThis study is testing if adding an experimental drug called berzosertib to a standard chemotherapy (carboplatin) works better for treating advanced prostate cancer that has spread and stopped responding to hormone therapy. It compares this new combination to the standard treatmen…
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 16, 2026 13:02 UTC
-
Targeted drug combo tested for Tough-to-Treat prostate cancer
Disease control OngoingThis study is testing whether a combination of two drugs, niraparib/abiraterone and prednisone, can help control advanced prostate cancer that has spread and has a specific genetic mutation called SPOP. The treatment aims to stop cancer cells from repairing themselves and reduce …
Matched conditions: CASTRATION-RESISTANT PROSTATE CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 13, 2026 20:19 UTC